Redvax Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Redvax General Information
Description
Operator of a biopharmaceutical company in Sweden. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of Cytomegalovirus (CMV).
Contact Information
Corporate Office
- Wagistrasse 23
- Schlieren
- 8952 Zurich
- Switzerland
Corporate Office
- Wagistrasse 23
- Schlieren
- 8952 Zurich
- Switzerland
Redvax Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 05-Jan-2015 | Completed | Pre-Clinical Trials | |||
1. Early Stage VC | Completed | Startup |
Redvax Former Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Redalpine | Venture Capital | Minority |
Redvax FAQs
-
Where is Redvax headquartered?
Redvax is headquartered in Zurich, Switzerland.
-
What industry is Redvax in?
Redvax’s primary industry is Drug Discovery.
-
Is Redvax a private or public company?
Redvax is a Private company.
-
What is Redvax’s current revenue?
The current revenue for Redvax is
. -
Who are Redvax’s investors?
Redalpine has invested in Redvax.
-
When was Redvax acquired?
Redvax was acquired on 05-Jan-2015.
-
Who acquired Redvax?
Redvax was acquired by Pfizer (Pharmaceuticals).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »